pp-153 Solution for injection
Dossier type
CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Lupus nephritis (SLE); autoimmune hepatitis
Clinical stage: Phase 2b
Modality: Small molecule
Mechanism / Target: Selective immunoproteasome (LMP7, β5i subunit) inhibitor — reduces MHC-I antigen presentation on APCs, dampens inflammatory cytokine production, reduces autoantibody-secreting plasma cells
Route / form: Subcutaneous injection (weekly)
Differentiation: Immunoproteasome-selective (spares constitutive proteasome → lower toxicity vs bortezomib); reduces anti-dsDNA antibodies and disease activity in Phase 1/2; novel target in lupus
Manufacturer #39182
Clinical-stage autoimmune disease company focused on immunoproteasome inhibition. Targets plasma cell and innate immune activity driving lupus and other antibody-mediated diseases. Wholly owned selective immunoproteasome inhibitor advancing in Phase 2b.
None